These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

670 related articles for article (PubMed ID: 27347935)

  • 21. Modification of the Genome of Domestic Animals.
    Lotti SN; Polkoff KM; Rubessa M; Wheeler MB
    Anim Biotechnol; 2017 Jul; 28(3):198-210. PubMed ID: 28103141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Applications of ZFN, TALEN and CRISPR/Cas9 techniques in disease modeling and gene therapy].
    Zhao G; Pu J; Tang B
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2016 Dec; 33(6):857-862. PubMed ID: 27984622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Applications of Genome Editing Tools in Stem Cells Towards Regenerative Medicine: An Update.
    Kues WA; Kumar D; Selokar NL; Talluri TR
    Curr Stem Cell Res Ther; 2022; 17(3):267-279. PubMed ID: 34819011
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted Gene Editing in Human Pluripotent Stem Cells Using Site-Specific Nucleases.
    Merkert S; Martin U
    Adv Biochem Eng Biotechnol; 2018; 163():169-186. PubMed ID: 29124278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Research on genodermatoses using novel genome-editing tools.
    Lehmann J; Seebode C; Emmert S
    J Dtsch Dermatol Ges; 2017 Aug; 15(8):783-789. PubMed ID: 28622433
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induced Pluripotency and Gene Editing in Disease Modelling: Perspectives and Challenges.
    Seah YF; El Farran CA; Warrier T; Xu J; Loh YH
    Int J Mol Sci; 2015 Dec; 16(12):28614-34. PubMed ID: 26633382
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene targeting technologies in rats: zinc finger nucleases, transcription activator-like effector nucleases, and clustered regularly interspaced short palindromic repeats.
    Mashimo T
    Dev Growth Differ; 2014 Jan; 56(1):46-52. PubMed ID: 24372523
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene editing and CRISPR in the clinic: current and future perspectives.
    Hirakawa MP; Krishnakumar R; Timlin JA; Carney JP; Butler KS
    Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32207531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CRISPR Genome Engineering for Human Pluripotent Stem Cell Research.
    Chaterji S; Ahn EH; Kim DH
    Theranostics; 2017; 7(18):4445-4469. PubMed ID: 29158838
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genome engineering tools for building cellular models of disease.
    Lin J; Musunuru K
    FEBS J; 2016 Sep; 283(17):3222-31. PubMed ID: 27218233
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The CRISPR-Cas system for plant genome editing: advances and opportunities.
    Kumar V; Jain M
    J Exp Bot; 2015 Jan; 66(1):47-57. PubMed ID: 25371501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic editing of hepatocyte genome in vivo.
    Ruiz de Galarreta M; Lujambio A
    J Hepatol; 2017 Oct; 67(4):818-828. PubMed ID: 28527665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CRISPR therapeutic tools for complex genetic disorders and cancer (Review).
    Baliou S; Adamaki M; Kyriakopoulos AM; Spandidos DA; Panayiotidis M; Christodoulou I; Zoumpourlis V
    Int J Oncol; 2018 Aug; 53(2):443-468. PubMed ID: 29901119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genome editing technologies to fight infectious diseases.
    Trevisan M; Palù G; Barzon L
    Expert Rev Anti Infect Ther; 2017 Nov; 15(11):1001-1013. PubMed ID: 29090592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Genome-editing: focus on the off-target effects].
    He X; Gu F
    Sheng Wu Gong Cheng Xue Bao; 2017 Oct; 33(10):1757-1775. PubMed ID: 29082723
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic correction using engineered nucleases for gene therapy applications.
    Li HL; Nakano T; Hotta A
    Dev Growth Differ; 2014 Jan; 56(1):63-77. PubMed ID: 24329887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CRISPR/Cas9 Editing of Murine Induced Pluripotent Stem Cells for Engineering Inflammation-Resistant Tissues.
    Brunger JM; Zutshi A; Willard VP; Gersbach CA; Guilak F
    Arthritis Rheumatol; 2017 May; 69(5):1111-1121. PubMed ID: 27813286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Genome Editing Tools and their Application in Experimental Ophthalmology].
    Yanik M; Wende W; Stieger K
    Klin Monbl Augenheilkd; 2017 Mar; 234(3):329-334. PubMed ID: 28114701
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induced Pluripotent Stem Cells in the Era of Precise Genome Editing.
    Punetha M; Saini S; Chaudhary S; Yadav PS; Whitworth K; Green J; Kumar D; Kues WA
    Curr Stem Cell Res Ther; 2024; 19(3):307-315. PubMed ID: 36880183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current and future delivery systems for engineered nucleases: ZFN, TALEN and RGEN.
    Ul Ain Q; Chung JY; Kim YH
    J Control Release; 2015 May; 205():120-7. PubMed ID: 25553825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.